| Document |
Document Title |
|
WO/2019/040335A1 |
The present invention relates to derivatives of the sesquiterpene lactone micheliolide, methods and compositions for their preparation, and methods for using the micheliolide derivatives in pharmaceutical compositions as anticancer and a...
|
|
WO/2019/039705A1 |
The present invention relates to a method for separating 5-hydroxymethyl-2-furfural (HMF) and dimethyl sulfoxide (DMSO), the method comprising the steps of: (a) preparing a mixture solution comprising HMF and DMSO; and (b) mixing an orga...
|
|
WO/2019/040005A1 |
Disclosed herein is a nanoparticulate material comprising graphene quantum dots (GQDs) having a first and second surface, each surface comprising one or more functional groups; and may additionally comprises of metal-containing nanoparti...
|
|
WO/2019/034461A1 |
Described is a process of separating 2,5-diformylfuran from an aqueous mixture comprising dissolved 5-(hydroxymethyl)furfural, dissolved 2,5-diformylfuran and a buffer substance, comprising the step of (a) cooling down the mixture so tha...
|
|
WO/2019/033219A1 |
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show util...
|
|
WO/2019/035412A1 |
This organic electroluminescence element includes an anode, a cathode, and an organic layer disposed between the anode and the cathode. The organic layer includes a light-emitting layer and at least one layer disposed between the light-e...
|
|
WO/2019/036374A1 |
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula (I). The compounds are useful for treating inflammatory and autoimmune diseases.
|
|
WO/2019/031833A1 |
Disclosed are a compound represented by chemical formula 1, an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode, and an electronic devi...
|
|
WO/2019/031605A1 |
Provided is a fused ring compound which exhibits excellent charge transport ability. A fused ring compound which is represented by formula (1) and has a specific structure.
|
|
WO/2019/025540A1 |
The invention relates to 3-acyl-benzamides of formula (I) as herbicides. In formula (I) X, Y, Z and Rx represent radicals such as alkyl, cycloalkyl and halogen.
|
|
WO/2019/025467A1 |
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful fo...
|
|
WO/2019/024635A1 |
Provided are a 1,3-di-substituted ketene compound having a structure as represented by formula (I) and an application thereof. Such a type of compound primarily activates peroxisome proliferator-activated receptor (PPAR) α, and also act...
|
|
WO/2019/021146A1 |
Provided is a novel organic compound. Also provided is a novel organic compound having hole transport properties. Further provided is a novel hole transport material. A novel light-emitting element is also provided. A light-emitting elem...
|
|
WO/2019/020654A1 |
The present application relates to a spirobifluorene derivative of a specific formula (I) which is suitable for use in electronic devices.
|
|
WO/2019/023147A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...
|
|
WO/2019/020773A1 |
The present invention relates to a new bio-sourced vanillin and/or ethylvanillin, containing specific impurities. The invention further relates to a process for their preparations and the use of such compounds.
|
|
WO/2019/023145A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...
|
|
WO/2019/022562A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting element comprising the same.
|
|
WO/2019/018588A1 |
Zinc:usnic acid complexes having a 1:2 zinc to usnate molar ratio and methods of preparing them. Oral care compositions comprising the Zn:usnate complexes may be useful to improve oral health.
|
|
WO/2019/017730A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
|
WO/2019/017468A1 |
Provided is a production method by which 2,5-bis(aminomethyl)furan can be efficiently produced. This 2,5-bis(aminomethyl)furan production method comprises a step for producing 2,5-bis(aminomethyl)furan by reacting hydrogen and an amine c...
|
|
WO/2019/018287A1 |
Disclosed herein are personal care compositions comprising Zn:usnate complexes having a 1:2 zinc to usnate molar ratio. Methods of making and using the compositions are also provided. The personal care compositions may include a cleansin...
|
|
WO/2019/017734A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
|
WO/2019/017731A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
|
WO/2019/016269A1 |
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.
|
|
WO/2019/013299A1 |
The present invention provides a thermally conductive material that has excellent thermal conductivity. The present invention also provides: a device that is provided with a thermally conductive layer that includes the thermally conducti...
|
|
WO/2019/011285A1 |
Disclosed are a tetrahydronaphtho[1,2-b]furan-2(3H)-one derivative having a chemical structure as shown in formula I, and a preparation method therefor. The tetrahydronaphtho[1,2-b]furan-2(3H)-one derivative can be used in the preparatio...
|
|
WO/2019/011200A1 |
The invention relates to a preparation method of a pyridinecarboxamide derivative and an intermediate thereof wherein the reaction step is shortened, the reaction yield is improved, the method is simple and easy to control, and is advant...
|
|
WO/2019/013509A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2019/014382A1 |
The present disclosure provides processes for the purification of 2,5-furandicarboxylic acid (FDCA). The present disclosure further provides crystalline preparations of purified FDCA, as well as processes for making the same. In addition...
|
|
WO/2019/013487A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2019/013503A1 |
The present invention relates to a novel organic compound and an organic electroluminescent element including the same and, more specifically, to: a novel dibenzofuran-based compound having excellent thermal stability, carrier transport ...
|
|
WO/2019/014393A1 |
The present disclosure provides processes for the production of 2,5-furandicarboxylic acid (FDCA) from various substrates, including C6-aldaric acids and lactones of C6-aldaric acids.
|
|
WO/2019/007415A1 |
Disclosed are a furan-naphthoquinone-based sulfoximine derivative as shown in formula (I), a pharmaceutical composition containing the derivative and the use of the derivative as an STAT3 inhibitor.
|
|
WO/2019/007821A1 |
The invention relates to 4,6-dihalogen-dibenzothiophene and 4,6-dihalogen-dibenzofuran-3-thioether derivatives of formula (I), in which W, X, R1, R2, A1, Z1 and n are defined as cited in claim 1, to their production, their use as compone...
|
|
WO/2019/004777A1 |
An embodiment of the present invention provides a method for preparing 2,5-furandimethylcarboxylate (FDMC), the method comprising a step for preparing 2,5-furandimethylcarboxylate (FDMC) by an acidic esterification reaction of a reactant...
|
|
WO/2019/002190A1 |
The present application relates to a spirobifluorene derivative of a specific formula (I) which is suitable for use in electronic devices.
|
|
WO/2019/000069A1 |
Disclosed is a cost-effective process for catalytic conversion of simple C6-based sugars (such as glucose and fructose) and industrial-grade sugar syrups derived from starch (such as different grades of High Fructose Corn Syrup) and cell...
|
|
WO/2019/004614A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting element using same.
|
|
WO/2018/236928A1 |
The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to p...
|
|
WO/2018/236913A1 |
Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used f...
|
|
WO/2018/236146A1 |
The present invention relates to a compound of chemical formula 1, a coating composition comprising the same, and an organic light emitting element comprising the same.
|
|
WO/2018/235012A1 |
Process for producing levulinic acid, wherein a carbohydrate-based substrate is subjected to a treatment step in aqueous environment at acid pH at a temperature from 120°C to 200°C, so as to obtain a reaction mixture comprising levulin...
|
|
WO/2018/232527A1 |
The present invention describes complex topical aqueous compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic...
|
|
WO/2018/236182A1 |
The present specification provides a compound of chemical formula 1 and an organic electroluminescent device comprising same.
|
|
WO/2018/236218A1 |
The present invention, relates to processes for the production and conversion of furan compounds. In certain embodiments the invention concerns the conversion of furfural compounds into a so-called Knoevenagel products and for the furthe...
|
|
WO/2018/236948A1 |
The present invention relates to a process for making the esters of 2,5-furandicarboxylic acid, and particularly the dimethyl, diethyl or dipropyl esters of FDCA for use as monomers in the production of polyesters and other types of poly...
|
|
WO/2018/235926A1 |
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...
|
|
WO/2018/235953A1 |
This compound is represented by formula (1).
|
|
WO/2018/229342A1 |
A method for extracting furfural and optionally (an) organic acid(s) from an aqueous solution is disclosed. The method may comprise extracting of furfural and optionally (an) organic acid(s) from an aqueous solution using isophorone as a...
|
